COCP news

Cocrystal Pharma entered into a securities purchase agreement with OPKO Health, Inc. for the sale of common stock. The terms set a floor for the share price based on the Nasdaq Consolidated Bid Price.

Cocrystal Pharma announced the appointment of James Sapirstein as Chief Executive Officer effective June 3, 2026, with a $265,000 annual salary and 235,000 stock options. The leadership change signals organizational transition and provides equity incentive alignment with company performance.

Cocrystal Pharma appointed James Sapirstein as Chief Executive Officer effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Sapirstein brings 23 product launches and extensive antiviral development experience from prior roles at Contravir, Tobira, and Gilead Sciences.

Cocrystal Pharma announced discovery of novel direct-acting antivirals with pan-viral activity against hantavirus, bunyavirus and influenza, targeting a conserved viral replication enzyme region. The announcement addresses significant unmet medical needs for hantavirus and bunyavirus, which currentl…